替考拉宁单独及联合用药时的时间杀菌试验的抗葡萄球菌活性。
Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay.
机构信息
Department of Pathology, Hershey Medical Center, Hershey, PA 17033, USA.
出版信息
Antimicrob Agents Chemother. 2010 May;54(5):2201-5. doi: 10.1128/AAC.01143-09. Epub 2010 Feb 16.
Abstract
Synergy time-kill studies against 40 methicillin-resistant Staphylococcus aureus (MRSA) strains of differing resistance phenotypes were conducted. Subinhibitory concentrations of telavancin were combined with sub-MIC concentrations of other antimicrobial agents that might be used in combination with telavancin to provide Gram-negative coverage. The highest incidence of synergy was found after 24 h with gentamicin (90% of strains), followed by ceftriaxone (88%), rifampin and meropenem (each 65%), cefepime (45%), and ciprofloxacin (38%) for combinations tested at or below the intermediate breakpoint for each agent.
摘要
对 40 株不同耐药表型的耐甲氧西林金黄色葡萄球菌（MRSA）菌株进行协同时间杀伤研究。替考拉宁的亚抑菌浓度与其他抗菌药物的亚 MIC 浓度联合使用，这些药物可能与替考拉宁联合使用以提供革兰氏阴性菌覆盖。在 24 小时后，与氨基糖苷类药物（90%的菌株）、头孢曲松（88%）、利福平、美罗培南（各 65%）、头孢吡肟（45%）和环丙沙星（38%）联合使用时，协同作用的发生率最高，这些组合均低于每种药物的中介折点。
相似文献
1
Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay.
Antimicrob Agents Chemother. 2010 May;54(5):2201-5. doi: 10.1128/AAC.01143-09. Epub 2010 Feb 16.
2
Comparative activities of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureus.
Antimicrob Agents Chemother. 2013 Jun;57(6):2678-83. doi: 10.1128/AAC.02127-12. Epub 2013 Apr 1.
3
Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
Antimicrob Agents Chemother. 2009 Jul;53(7):2928-33. doi: 10.1128/AAC.01544-08. Epub 2009 May 4.
4
Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
Antimicrob Agents Chemother. 2010 May;54(5):2258-61. doi: 10.1128/AAC.01350-09. Epub 2010 Feb 9.
5
Evaluation of Telavancin Alone and Combined with Ceftaroline or Rifampin against Methicillin-Resistant Staphylococcus aureus in an Biofilm Model.
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00567-18. Print 2018 Aug.
6
In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms.
J Antimicrob Chemother. 2003 May;51(5):1203-11. doi: 10.1093/jac/dkg238. Epub 2003 Apr 14.
7
Evaluation of Oritavancin Combinations with Rifampin, Gentamicin, or Linezolid against Prosthetic Joint Infection-Associated Methicillin-Resistant Staphylococcus aureus Biofilms by Time-Kill Assays.
Antimicrob Agents Chemother. 2018 Sep 24;62(10). doi: 10.1128/AAC.00943-18. Print 2018 Oct.
8
Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients.
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.00956-18. Print 2018 Sep.
9
Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies.
Antimicrob Agents Chemother. 2009 Oct;53(10):4217-24. doi: 10.1128/AAC.00742-09. Epub 2009 Jul 20.
10
Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents.
Antimicrob Agents Chemother. 2014 Oct;58(10):6251-4. doi: 10.1128/AAC.02932-14. Epub 2014 Jul 14.
引用本文的文献
1
Antibiotic synergy against : a systematic review and meta-analysis.
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0119924. doi: 10.1128/aac.01199-24. Epub 2025 Jun 17.
2
Evaluation of Telavancin Alone and Combined with Ceftaroline or Rifampin against Methicillin-Resistant Staphylococcus aureus in an Biofilm Model.
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00567-18. Print 2018 Aug.
3
Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides.
Clin Pharmacokinet. 2018 Jul;57(7):797-816. doi: 10.1007/s40262-017-0623-4.
4
Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.
Ther Adv Respir Dis. 2016 Aug;10(4):368-78. doi: 10.1177/1753465816651594. Epub 2016 Jun 23.
5
Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.
Drugs. 2015 Dec;75(18):2073-95. doi: 10.1007/s40265-015-0505-8.
6
Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents.
Antimicrob Agents Chemother. 2014 Oct;58(10):6251-4. doi: 10.1128/AAC.02932-14. Epub 2014 Jul 14.
7
Telavancin: a review of its use in patients with nosocomial pneumonia.
Drugs. 2013 Nov;73(16):1829-39. doi: 10.1007/s40265-013-0144-x.
8
Comparative activities of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureus.
Antimicrob Agents Chemother. 2013 Jun;57(6):2678-83. doi: 10.1128/AAC.02127-12. Epub 2013 Apr 1.
9
In Vitro Synergy of Telavancin and Rifampin Against Enterococcus faecium Resistant to Both Linezolid and Vancomycin.
Ochsner J. 2013 Spring;13(1):61-5.
10
Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
PLoS One. 2012;7(7):e42103. doi: 10.1371/journal.pone.0042103. Epub 2012 Jul 24.
本文引用的文献
1
Antibiotics for emerging pathogens.
Science. 2009 Aug 28;325(5944):1089-93. doi: 10.1126/science.1176667.
2
Phenol-soluble modulin alpha 3 enhances the human neutrophil lysis mediated by Panton-Valentine leukocidin.
J Infect Dis. 2009 Sep 1;200(5):715-23. doi: 10.1086/605332.
3
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.
Clin Infect Dis. 2009 Jan 1;48(1):1-12. doi: 10.1086/595011.
4
Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.
Clin Infect Dis. 2008 Jun 1;46(11):1683-93. doi: 10.1086/587896.
5
Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
Antimicrob Agents Chemother. 2008 Jul;52(7):2383-8. doi: 10.1128/AAC.01641-07. Epub 2008 Apr 28.
6
In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
J Antimicrob Chemother. 2008 Jul;62(1):116-21. doi: 10.1093/jac/dkn124. Epub 2008 Apr 19.
7
Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis.
Antimicrob Agents Chemother. 2007 Sep;51(9):3445-8. doi: 10.1128/AAC.00559-07. Epub 2007 Jul 9.
8
Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology.
Antimicrob Agents Chemother. 2007 Apr;51(4):1504-7. doi: 10.1128/AAC.01455-06. Epub 2007 Jan 12.
9
Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.
J Antimicrob Chemother. 2006 Aug;58(2):338-43. doi: 10.1093/jac/dkl235. Epub 2006 Jun 20.
10
Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.
Antimicrob Agents Chemother. 2006 Mar;50(3):1079-82. doi: 10.1128/AAC.50.3.1079-1082.2006.
Zotero 插件